Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1084/jem.20211862 http://scihub22266oqcxt.onion/10.1084/jem.20211862 34889942!8669500!34889942     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Exp+Med 2022 ; 219 (2): ä Nephropedia Template TP {{tp|p=34889942|t=2022. Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge |pdf=|usr=}}{{34889942}} gab.com Text Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge JO: J Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=34889942 #FOAvip In addition to providing partial protection against pediatric tuberculosis, vaccination with bacille Calmette-Guerin (BCG) has been reported to confer nonspecific resistance to unrelated pulmonary pathogens, a phenomenon attributed to the induction of long-lasting alterations within the myeloid cell compartment. Here, we demonstrate that intravenous, but not subcutaneous, inoculation of BCG protects human-ACE2 transgenic mice against lethal challenge with SARS-CoV-2 (SCV2) and results in reduced viral loads in non-transgenic animals infected with an alpha variant. The observed increase in host resistance was associated with reductions in SCV2-induced tissue pathology, inflammatory cell recruitment, and cytokine production that multivariate analysis revealed as only partially related to diminished viral load. We propose that this protection stems from BCG-induced alterations in the composition and function of the pulmonary cellular compartment that impact the innate response to the virus and ensuing immunopathology. While intravenous BCG vaccination is not a clinically acceptable practice, our findings provide an experimental model for identifying mechanisms by which nonspecific stimulation of the pulmonary immune response promotes host resistance to SCV2 lethality. Twit Text FOAVip Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge ????J Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=34889942 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34889942 #FOAvip English Wikipedia <ref>{{Cite pmid|34889942}}</ref> Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge #MMPMID34889942 Hilligan KL; Namasivayam S; Clancy CS; O'Mard D; Oland SD; Robertson SJ; Baker PJ; Castro E; Garza NL; Lafont BAP; Johnson R; Ronchese F; Mayer-Barber KD; Best SM; Sher A J Exp Med 2022[Feb]; 219 (2): ä PMID34889942show ga In addition to providing partial protection against pediatric tuberculosis, vaccination with bacille Calmette-Guerin (BCG) has been reported to confer nonspecific resistance to unrelated pulmonary pathogens, a phenomenon attributed to the induction of long-lasting alterations within the myeloid cell compartment. Here, we demonstrate that intravenous, but not subcutaneous, inoculation of BCG protects human-ACE2 transgenic mice against lethal challenge with SARS-CoV-2 (SCV2) and results in reduced viral loads in non-transgenic animals infected with an alpha variant. The observed increase in host resistance was associated with reductions in SCV2-induced tissue pathology, inflammatory cell recruitment, and cytokine production that multivariate analysis revealed as only partially related to diminished viral load. We propose that this protection stems from BCG-induced alterations in the composition and function of the pulmonary cellular compartment that impact the innate response to the virus and ensuing immunopathology. While intravenous BCG vaccination is not a clinically acceptable practice, our findings provide an experimental model for identifying mechanisms by which nonspecific stimulation of the pulmonary immune response promotes host resistance to SCV2 lethality. |Administration, Intravenous[MESH] |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Animals[MESH] |BCG Vaccine/*immunology[MESH] |COVID-19/*immunology[MESH] |Chemokines/metabolism[MESH] |Humans[MESH] |Inflammation/pathology[MESH] |Mice[MESH] |Mice, Inbred C57BL[MESH] |Mice, Transgenic[MESH] |SARS-CoV-2/*immunology[MESH]Intravenous administration of BCG protects mice against lethal SARS-Co(epmc).pdf DeepDyve Pubget Overpricing